Ph2 Open-Label Randomized Global Study of Two Telisotuzumab Vedotin Regimens

Phase II Clinical Trial

M25-274; A Phase 2 Open-Label Randomized Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing EGFR Wildtype Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Indication: Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer
Trial Number: 06568939
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations